

REMARKS

Claims 1-38 are pending in the application. Claims 3-6, 9-18, 21, 23, and 25-38 have been cancelled. Accordingly, Claims 1-2, 7-8, and 19-20, 22, and 24 are under consideration. Claim 1, and dependent Claims 2, 7-8, and 19 have been amended to relate to subject matter within the scope of Claim 1 wherein Z is pyrrolidinyl moiety and is directed to the elected subject matter in the present application. Claim 20 has been amended to clarify that claimed compositions comprise compounds of formula I in Claim 1. Applicants respectfully reserve the right to file divisional applications on any non-pending or non-elected subject matter.


Claims 25-28 have been rejected pursuant to 35 U.S.C. § 112, first paragraph. Claims 21, 22, and 25-28 also have been rejected pursuant to 35 U.S.C. § 112, second paragraph. Applicants respectfully traverse the rejections.

Claims 21, 23, 25-28 have been cancelled. Pending Claims 22 and 24 relate to a method of treating a disorder selected from the group consisting of Alzheimer's disease, Parkinson's disease, attention deficit hyperactivity disorder, depression, nicotinic withdrawal syndrome, pain, Tourette's syndrome, and schizophrenia, and more specifically to a method of treating pain, respectively. It is respectfully submitted the recitation of the identified disorders more particularly points out and distinctly claims the invention.

The Examiner is cordially invited to contact the undersigned by telephone at the phone number provided below to further facilitate the prosecution of the application, if necessary.

ABBOTT LABORATORIES
Customer No. 23492
Telephone: (847) 937-8272
Facsimile: (847) 938-2623

Respectfully submitted,
Schrimpf, *et al.*



Portia Chen
Registration No. 44,075
Attorney for Applicants